Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Items 501–600 of 1,001
Choudhury, R. P., Birks, J. S., Mani, V., Biasiolli, L., Robson, M. D., L'Allier, P. L., Gingras, M.-A., Alie, N., McLaughlin, M. A., Basson, C. T., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.768 · Cited by 90
Role of the inflammasome in insulin resistance and type 2 diabetes mellitus
Lu, S., Li, Y., Qian, Z., Zhao, T., Feng, Z., Weng, X., & Yu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1052756 · Cited by 106
Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., Priori, R., Talarico, R., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00380 · Cited by 91
Thoudam, T., Jeon, J.-H., Ha, C.-M., & Lee, I.-K. (2016) · Mediators of Inflammation · doi:10.1155/2016/1851420 · Cited by 87
Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells
Jager, J., Aparicio‐Vergara, M., & Aouadi, M. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12483 · Cited by 90
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases
Owyang, A. M., Issafras, H., Corbin, J., Ahluwalia, K., Larsen, P., Pongo, E., Handa, M., Horwitz, A. H., Roell, M. K., Haak‐Frendscho, M., et al. (2011) · mAbs · doi:10.4161/mabs.3.1.13989 · Cited by 93
Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals
Mercer, E., Rekedal, L., Garg, R., Lü, B., Massarotti, E. M., & Solomon, D. H. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3868 · Cited by 94
Bidirectional crosstalk between neutrophils and adipocytes promotes adipose tissue inflammation
Watanabe, Y., Nagai, Y., Honda, H., Okamoto, N., Yanagibashi, T., Ogasawara, M., Yamamoto, S., Imamura, R., Takasaki, I., Hara, H., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900477rr · Cited by 83
“Indeed, randomized clinical trials have shown that anakinra, a recombinant human IL-1 receptor antagonist, improves type 2 diabetes by reducing systemic inflammation (8, 9).”
BackgroundFilippov, S., Pinkosky, S. L., Lister, R. J., Pawloski, C., Hanselman, J. C., Cramer, C. T., Srivastava, R. A. K., Hurley, T. R., Bradshaw, C. D., Spahr, M. A., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m035212 · Cited by 90
Glas, R., Sauter, N. S., Schulthess, F. T., Shu, L., Oberholzer, J., & Maedler, K. (2009) · Diabetologia · doi:10.1007/s00125-009-1349-0 · Cited by 90
“Results from a clinical study show that IL-1Ra improves glycaemic control and beta cell function in patients with type 2 diabetes [ 13 ].”
MicroRNA Post-transcriptional Regulation of the NLRP3 Inflammasome in Immunopathologies
Tezcan, G., Martynova, E. V., Gilazieva, Z. E., McIntyre, A., Rizvanov, A. A., & Khaiboullina, S. F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00451 · Cited by 85
Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
Velikova, T. V., Kabakchieva, P., Assyov, Y. S., & Georgiev, T. (2021) · BioMed Research International · doi:10.1155/2021/7297419 · Cited by 95
The emerging role of interleukin‐1β in autoinflammatory diseases
Lachmann, H. J., Quartier, P., So, A. K.-L., & Hawkins, P. N. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30105 · Cited by 97
Yin, Z., Deng, T., Peterson, L. E., Yu, R., Lin, J., Hamilton, D. J., Reardon, P. R., Sherman, V., Winnier, G. E., Zhan, M., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.06.018 · Cited by 85
“, 2006), which is implicated in beta-cell dysfunction and systemic inflammation in type 2 diabetes (Cavelti-Weder et al., 2012; Larsen et al., 2007) as well as unstable angina (Ridker et al.”
BackgroundInterleukin 1 gene polymorphism and susceptibility to disease
Khazim, K., Azulay, E. E., Kristal, B., & Cohen, I. (2017) · Immunological Reviews · doi:10.1111/imr.12620 · Cited by 90
Inflammatory Caspases in Innate Immunity and Inflammation
Yazdi, A. S., Guarda, G., D’Ombrain, M. C., & Drexler, S. K. (2010) · Journal of Innate Immunity · doi:10.1159/000283688 · Cited by 94
Interleukin-1 signaling contributes to acute islet compensation
Hajmrle, C., Smith, N. P., Spigelman, A. F., Dai, X.-Q., Senior, L., Bautista, A., Ferdaoussi, M., & MacDonald, P. E. (2016) · JCI Insight · doi:10.1172/jci.insight.86055 · Cited by 88
Diacerein ameliorates letrozole-induced polycystic ovarian syndrome in rats
Ibrahim, Y. F., Alorabi, M., Abdelzaher, W. Y., Toni, N. D. M., Thabet, K., Hegazy, A., Bahaa, H. A., Batiha, G. E., Welson, N. N., Morsy, M. A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112870 · Cited by 89
Reiner, A. P., Wurfel, M. M., Lange, L. A., Carlson, C. S., Nord, A. S., Carty, C. L., Rieder, M. J., Desmarais, C., Jenny, N. S., Iribarren, C., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.167437 · Cited by 85
Inflammasome and cytokine blocking strategies in autoinflammatory disorders
Moll, M., & Kuemmerle-Deschner, J. B. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.008 · Cited by 90
Platelet‐Activation Mechanisms and Vascular Remodeling
Rubenstein, D. A., & Yin, W. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170049 · Cited by 92
Verma, G., & Datta, M. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0498-4 · Cited by 90
Butyrate modulates diabetes-linked gut dysbiosis: epigenetic and mechanistic modifications
Noureldein, M. H., Bitar, S., Youssef, N., Azar, S., & Eid, A. A. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0132 · Cited by 84
Shridas, P., De Beer, M. C., & Webb, N. R. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002428 · Cited by 82
“Consistent with this concept, randomized clinical trials have shown that blocking IL-1 signaling leads to a sustained reduction in systemic inflammation and improvement in type 2 diabetes patients (3).”
BackgroundBrooks-Worrell, B., & Palmer, J. P. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04501.x · Cited by 82
Carbon monoxide negatively regulates NLRP3 inflammasome activation in macrophages
Jung, S. S., Moon, J., Xu, J., Ifedigbo, E., Ryter, S. W., Choi, A. M. K., & Nakahira, K. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00400.2014 · Cited by 85
Pirzada, R. H., Javaid, N., & Choi, S. (2020) · Genes · doi:10.3390/genes11020131 · Cited by 87
“Type 2 diabetes Interleukin 1 receptor antagonist (IL‐1Ra) Anakinra [106]”
BackgroundInfluentialDula, S. B., Jecmenica, M., Wu, R., Jahanshahi, P., Verrilli, G. M., Carter, J. D., Brayman, K. L., & Nunemaker, C. S. (2010) · Cell Calcium · doi:10.1016/j.ceca.2010.07.007 · Cited by 83
Targeting inflammation in the treatment of type 2 diabetes
Donath, M. Y. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12172 · Cited by 83
Self-citationEndoplasmic reticulum stress alters ryanodine receptor function in the murine pancreatic β cell
Yamamoto, W. R., Bone, R. N., Sohn, P., Syed, F., Reissaus, C. A., Mosley, A. L., Wijeratne, A. B., True, J. D., Tong, X., Kono, T., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005683 · Cited by 96
Elmadbouh, I. S., & Singla, D. K. (2021) · Cells · doi:10.3390/cells10102640 · Cited by 85
A decade of innovation in pharmaceutical R&D: the Chorus model
Owens, P. K., Raddad, E., Miller, J. W., Stille, J. R., Olovich, K. G., Smith, N. V., Jones, R. S., & Scherer, J. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4497 · Cited by 90
Effect of interleukin 1β inhibition in cardiovascular disease
Qamar, A., & Rader, D. J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328359b0a6 · Cited by 80
Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes
Lei, Y., Devarapu, S. K., Motrapu, M., Cohen, C. D., Lindenmeyer, M. T., Moll, S., Kumar, S. V. R., & Anders, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01223 · Cited by 82
Meier, D. T., Morcos, M., Samarasekera, T., Zraika, S., Hull, R. L., & Kahn, S. E. (2014) · Diabetologia · doi:10.1007/s00125-014-3304-y · Cited by 82
McDermott, M., & Tschopp, J. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.005 · Cited by 85
Cytokines in diabetic nephropathy
Wu, C., Sytwu, H., & Lin, Y. (2012) · Advances in clinical chemistry · doi:10.1016/b978-0-12-394317-0.00014-5 · Cited by 81
Transforming Growth Factor-β1 and Incident Type 2 Diabetes
Herder, C., Zierer, A., Koenig, W., Roden, M., Meisinger, C., & Thorand, B. (2009) · Diabetes Care · doi:10.2337/dc09-0476 · Cited by 81
Zhao, G., Dharmadhikari, G., Maedler, K., & Meyer‐Hermann, M. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003798 · Cited by 95
Proteomics Analysis of Cytokine-induced Dysfunction and Death in Insulin-producing INS-1E Cells
D’Hertog, W., Overbergh, L., Lage, K., Ferreira, G. B., Maris, M., Gysemans, C. A., Flamez, D., Cardozo, A. K., den Bergh, G. V., Schoofs, L., et al. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700085-mcp200 · Cited by 87
Type 2 diabetes and viral infection; cause and effect of disease
Wensveen, T. T., Gašparini, D., Rahelić, D., & Wensveen, F. M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108637 · Cited by 94
“A small-scale 13-week study in which patients with T2D received an interleukin-1 receptor antagonist caused a significant decrease in HbA1c levels and a reduction in the ratio of pro-insulin to insulin [111].”
BackgroundAhmed, M., Kumari, N., Mirgani, Z., Saeed, A., Ramadan, A., Ahmed, M. H., & Almobarak, A. O. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00965-2 · Cited by 88
Akash, M. S. H., Rehman, K., Ni, L., Gao, J., Sun, H., & Chen, S. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0843-0 · Cited by 83
Association of IL-1ra and Adiponectin With C-Peptide and Remission in Patients With Type 1 Diabetes
Pfleger, C., Mortensen, H. B., Hansen, L., Herder, C., Roep, B. O., Hoey, H., Aanstoot, H., Kočova, M., Schloot, N. C., & on behalf of the Hvidøre Study Group on Childhood Diabetes (2008) · Diabetes · doi:10.2337/db07-1697 · Cited by 86
“showed that administration of exogenous anti-inflammatory IL-1ra in type 2 diabetes patients could preserve endogenous insulin production and attenuated inflammation (16).”
BackgroundResultInfluentialAnti-inflammatory and anti-diabetic effects of brown seaweeds in high-fat diet-induced obese mice
Oh, J.-H., Kim, J., & Lee, Y. (2016) · Nutrition Research and Practice · doi:10.4162/nrp.2016.10.1.42 · Cited by 81
Mechanisms by which obesity impacts upon asthma
Umetsu, D. T. (2016) · Thorax · doi:10.1136/thoraxjnl-2016-209130 · Cited by 88
Ludvigsson, J., Hjorth, M., Chéramy, M., Axelsson, S., Pihl, M., Forsander, G., Nilsson, N.-O., Samuelsson, B.-O., Wood, T., Åman, J., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1988-1 · Cited by 83
“However, most attempts with immune intervention to preserve residual beta cell function have achieved limited benefits or have been associated with adverse effects [6-19].”
BackgroundGao, P., Meng, X., Su, H., He, F.-F., Chen, S., Tang, H. R., Tian, X., Fan, D., Wang, Y., Liu, J.-S., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.07.001 · Cited by 80
Inflammasome activation in obesity-related inflammatory diseases and autoimmunity.
Lukens, J. R., Dixit, V. D., & Kanneganti, T. (2011) · PubMed · Cited by 89
Islet amyloid polypeptide: Another key molecule in Alzheimer’s pathogenesis?
Zhang, Y., & Song, W. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.001 · Cited by 83
β-Cell failure in type 2 diabetes
Leibowitz, G., Kaiser, N., & Cerasi, E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00094.x · Cited by 78
Canakinumab for the treatment of chronic obstructive pulmonary disease
Rogliani, P., Calzetta, L., Ora, J., & Matera, M. G. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.01.005 · Cited by 80
Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack
Oates, J. R., McKell, M. C., Moreno-Fernandez, M. E., Damen, M. S. M. A., Deepe, G. S., Qualls, J. E., & Divanovic, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02893 · Cited by 73
“In addition, blockade of IL-1 signaling with anakinra improved glycemic control in patients with T2D (76), suggesting the importance of inflammatory mediators in liver disease pathogenesis.”
BackgroundAshrafizadeh, M., Kumar, A. P., Aref, A. R., Zarrabi, A., & Mostafavi, E. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s350250 · Cited by 78
T cells and their products in diabetic kidney disease
Liu, Y., Lv, Y., Zhang, T., Huang, T., Lang, Y., Sheng, Q., Liu, Y., Kong, Z., Gao, Y., Lu, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1084448 · Cited by 82
SAHLMAN, J., MIETTINEN, K., PEUHKURINEN, K., SEPPÄ, J., PELTONEN, M., HERDER, C., PUNNONEN, K., VANNINEN, E., GYLLING, H., PARTINEN, M., et al. (2009) · Journal of Sleep Research · doi:10.1111/j.1365-2869.2009.00787.x · Cited by 76
Pascual, V., Allantaz, F., Patel, P., Palucka, A. K., Chaussabel, D., & Banchereau, J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00643.x · Cited by 79
Abbate, A., Tassell, B. W. V., & Biondi‐Zoccai, G. (2012) · BioDrugs · doi:10.1007/bf03261881 · Cited by 84
Obesity, Inflammation, and Lung Injury (OILI): The Good
Wang, C. (2014) · Mediators of Inflammation · doi:10.1155/2014/978463 · Cited by 88
Lee, H.-Y., Kim, J., Quan, W., Lee, J.-C., Kim, M.-S., Kim, S.-H., Bae, J.-W., Hur, K. Y., & Lee, M.-S. (2016) · Autophagy · doi:10.1080/15548627.2016.1184799 · Cited by 76
Inflammation Markers in Type 2 Diabetes and the Metabolic Syndrome in the Pediatric Population
Reinehr, T., & Roth, C. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1110-5 · Cited by 83
Targeting inflammatory pathways for the treatment of cardiovascular disease
Ridker, P. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht398 · Cited by 80
Yan, Y., Li, S., Liu, Y., Bazzano, L., He, J., Mi, J., & Chen, W. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0913-2 · Cited by 82
Kim, Y. G., Ihm, C.-G., Lee, T. W., Lee, S. H., Jeong, K. H., Moon, J. Y., Chung, J.-H., Kim, S. K., & Kim, Y. H. (2012) · Transplantation · doi:10.1097/tp.0b013e3182497534 · Cited by 76
The Inflammasome and IL-1β: Implications for the Treatment of Inflammatory Diseases
Satoh, T. K., Otsuka, A., Contassot, E., & French, L. E. (2015) · Immunotherapy · doi:10.2217/imt.14.106 · Cited by 82
Böni-Schnetzler, M., Häuselmann, S. P., Dalmas, E., Meier, D. T., Thienel, C., Traub, S., Schulze, F., Steiger, L., Dror, E., Martin, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.063 · Cited by 71
Self-citationLiang, Y., Li, J., Xiao, H., He, Y., Zhang, L., & Yan, Y. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12643 · Cited by 81
Kono, H., Orlowski, G. M., Patel, Z., & Rock, K. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200136 · Cited by 75
Sumpter, K., Adhikari, S., Grishman, E. K., & White, P. C. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00761.x · Cited by 76
Sun, S., Xia, S., Ji, Y., Kersten, S., & Qi, L. (2012) · Diabetes · doi:10.2337/db11-1389 · Cited by 75
Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes
Cavelti‐Weder, C., Timper, K., Seelig, E., Keller, C., Osranek, M., Lässing, U., Spohn, G., Maurer, P., Müller, P., Jennings, G. T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.227 · Cited by 84
Self-citationKrüppel-Like Factors in Metabolic Homeostasis and Cardiometabolic Disease
Oishi, Y., & Manabe, I. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00069 · Cited by 89
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures
Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 80
Castillo, Í. M. P., Argilés, J. M. A., Rueda, R., Ramírez, M., & Pedrosa, J. M. L. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09954-9 · Cited by 81
Luís, J. P., Simões, C. J. V., & Brito, R. M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031731 · Cited by 76
Pedersen, S. S., Prause, M. C. B., Williams, K., Barrès, R., & Billestrup, N. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102312 · Cited by 78
“The abbreviations used are: ChIP, chromatin immunoprecipitation; CXCL1, (C-X-C motif) ligand 1; EMSA, electrophoretic mobility shift assay; FFAR, free fatty receptor; HDAC, histone deacetylase; IL-1β, interleukin-1β; iNOS, inducible nitric oxide synthase; NO, nitric oxide; NF-κB, nuclear factor-κB; P/ S, penicillin/st…”
BackgroundInfluentialCD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder
Wang, X., Liu, M., Zhang, J., Brown, N. K., Zhang, P., Zhang, Y., Liu, H., Du, X., Wu, W., Devenport, M., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.005 · Cited by 74
IL-1Ra and its Delivery Strategies: Inserting the Association in Perspective
Akash, M. S. H., Rehman, K., & Chen, S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1118-0 · Cited by 79
Westwell-Roper, C. Y., Nąckiewicz, D., Dan, M., & Ehses, J. A. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.4 · Cited by 75
Self-citationMori, M. A., Liu, M., Bezy, O., Almind, K., Shapiro, H., Kasif, S., & Kahn, C. R. (2010) · Diabetes · doi:10.2337/db10-0367 · Cited by 73
Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism
Postler, T. S., Peng, V., Bhatt, D. M., & Ghosh, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-97441-x · Cited by 75
Wu, M., Lee, M. Y. Y., Bahl, V., Traum, D., Schug, J., Kusmartseva, I., Atkinson, M. A., Fan, G., & Kaestner, K. H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109919 · Cited by 77
“The relevance of this observation to T2D pathogenesis in humans has been supported by clinical studies utilizing interleukin 1 beta (IL-1β) receptor antagonists or neutralizing antibodies to IL-1β (Cavelti-Weder et al., 2012; Larsen et al., 2007).”
MethodCytokine regulation of immune responses to Porphyromonas gingivalis: Cytokines and P. gingivalis
Taylor, J. J. (2010) · Periodontology 2000 · doi:10.1111/j.1600-0757.2009.00344.x · Cited by 85
Apoptosis of Beta Cells in Diabetes Mellitus
Rachakatla, A., Mudigonda, S., Kumar, K., & Hanumanth, S. R. (2014) · DNA and Cell Biology · doi:10.1089/dna.2014.2352 · Cited by 81
Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases
Singh, A. K., Talekar, M., Raikar, A., & Amiji, M. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.021 · Cited by 77
Lacraz, G., Giroix, M.-H., Kassis, N., Coulaud, J., Galinier, A., Noll, C., Cornut, M., Schmidlin, F., Paul, J., Janel, N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006963 · Cited by 76
Self-citationCoope, A., Torsoni, A. S., & Velloso, L. A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1065 · Cited by 71
The cephalic phase of insulin release is modulated by IL-1β
Wiedemann, S. J., TRIMIGLIOZZI, K. A., Dror, E., Meier, D. T., Molina‐Tijeras, J. A., Rachid, L., Foll, C. L., Magnan, C., Schulze, F., Stawiski, M., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.001 · Cited by 72
Self-citationHeavy arch: from inflammatory bowel diseases to metabolic disorders
Adolph, T. E., Meyer, M., Jukic, A., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2024-331914 · Cited by 74
Factors Determining Insulin Resistance in Chronic Hemodialysis Patients
Hung, A. M., & Ikizler, T. A. (2011) · Contributions to nephrology · doi:10.1159/000327177 · Cited by 75
Kumar, N. P., George, P. J., Kumaran, P., Dolla, C. K., Nutman, T. B., & Babu, S. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu329 · Cited by 78
Anti-cytokine therapies in T1D: Concepts and strategies
Nepom, G. T., Ehlers, M. R., & Mandrup-Poulsen, T. R. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.02.003 · Cited by 72
Self-citationLevy, H., Wang, X., Kaldunski, M. L., Jia, S., Kramer, J., Pavletich, S. J., Reske, M., Gessel, T., Yassai, M. B., Quasney, M. W., et al. (2012) · Genes and Immunity · doi:10.1038/gene.2012.41 · Cited by 73
Lorenzo, C., Hanley, A. J., & Haffner, S. M. (2013) · Diabetologia · doi:10.1007/s00125-013-3080-0 · Cited by 73
Christensen, D. P., Gysemans, C., Lundh, M., Dahllöf, M. S., Noesgaard, D., Schmidt, S. F., Mandrup, S., Birkbak, N., Workman, C. T., Piemonti, L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320850111 · Cited by 72
Self-citationDeshwal, S., Forkink, M., Hu, C.-H., Buonincontri, G., Antonucci, S., Sante, M. D., Murphy, M. P., Paolocci, N., Mochly‐Rosen, D., Krieg, T., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0071-1 · Cited by 75
Evasion of inflammasome activation by microbial pathogens
Ulland, T. K., Ferguson, P. J., & Sutterwala, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75254 · Cited by 75
“…disorders (75), such as systemic-onset juvenile idiopathic arthritis (76, 77), adult-onset Still disease (AOSD) (78, 79), gout (80), polyarticular juvenile idiopathic arthritis (sJIA) (81), diabetes (82), heart disease (83–85), and chronic granulomatous disease (86), among many others (87).”
Nąckiewicz, D., Dan, M., Speck, M., Chow, S., Chen, Y., Pospisilik, J. A., Verchere, C. B., & Ehses, J. A. (2019) · iScience · doi:10.1016/j.isci.2019.100775 · Cited by 76
Self-citationvan Asseldonk, E. J. P., van Poppel, P. C. M., Ballak, D. B., Stienstra, R., Netea, M. G., & Tack, C. J. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.06.003 · Cited by 72
Preservation of β-cell function by targeting β-cell mass
DEKONING, E., Bonner‐Weir, S., & Rabelink, T. J. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.02.001 · Cited by 82
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.